biomarker assay News
-
Glycotest™ Announces Grant of Japanese Patent
Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for earlystage liver cancer—has been granted. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality ...
-
MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation
MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the successful completion of its first clinical trial of anle138b (NCT04208152) in healthy volunteers. The Company’s lead candidate, which was administered in doses of up to 300 mg daily, demonstrated excellent safety and ...
By MODAG GmbH
-
Glycotest™ Intellectual Property Portfolio Expanded by United Sates, European and Australian Patents
Glycotest, Inc. announced today that a European patent has been granted and additional United States and Australian patents have been allowed. Together these patents will extend protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver ...
-
Iron Horse Diagnostics, Inc. Announces License Agreement with Global IVD Powerhouse EUROIMMUN AG for First to Market ALS Diagnostic Test
Iron Horse Dx announced today that they have signed a non-exclusive license agreement with Euroimmun Medizinische Labordiagnostika AG (Lübeck, Germany) to launch the first biological diagnostic test for Amyotrophic Lateral Sclerosis (“ALS”), more commonly known as Lou Gehrig’s Disease. ALS is a progressive neurological disease with an average life span of 3-5 years from ...
By nVector
-
Creative Proteomics Cytokine Unveils Disease Cytokine Assays for Disease Diagnosis
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced Disease Cytokine Assays to help researchers obtain higher quality scientific research data. Cytokines, ...
-
Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions
Alfa Chemistry serves as an emerging pharmaceutical research organization with a mission to revolutionize the field of preclinical drug research with its wide range of comprehensive services. With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to streamline the drug development ...
-
Glycotest Intellectual Property Portfolio Strengthened by Grant of Japanese Patent
Glycotest Inc., announced today that a Japanese patent has been granted that provides important protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and ...
-
Glycotest Innovator Joins the Medical University of South Carolina as the New SmartState Endowed Chair of Proteomic Biomarkers
Glycotest, Inc. innovator Professor Anand Mehta, a leader in the development of glycoproteomic technologies for the discovery of novel cancer biomarkers, joins the Medical University of South Carolina (MUSC) and Hollings Cancer Center, Charleston, SC, as the new SmartState Endowed Chair of Proteomic Biomarkers, the company announced today (see MUSC). Mehta, whose work has resulted in 79 ...
-
Glycotest™ HCC Panel Completes Successful Clinical Product Evaluation
Glycotest Inc., announced today that it successfully completed a clinical evaluation of its HCC Panel in China. In a blinded evaluation of 149 HCC patient and control samples, the HCC Panel achieved an AUROC of 0.97. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to ...
-
Thermo Fisher Scientific Supports Sepsis Awareness Month in September
Thermo Fisher Scientific Inc., the world leader in serving science, announces its support of Sepsis Awareness Month to drive awareness around sepsis, a complex clinical syndrome and a leading cause of death globally.1 Throughout the month of September, supporters are encouraged to join together to raise sepsis awareness through posting on social media, handing out brochures or stickers, giving ...
-
Glycotest™ Closes $10 Million Series A Financing with Fosun Pharma
Glycotest Inc., Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today the close of a Series A funding round of $10 million from Shanghai Fosun Pharmaceutical Co., Ltd. (“Fosun Pharma”). The transaction includes an equity investment of an initial tranche of $3 million with the remaining $7 ...
-
New Quantitative Approach to Autism Diagnosis - IEEE Pulse
Only a few years ago, leading autism expert David Amaral described the disorder as a lifelong disability. Today, he acknowledges that description is no longer true. “Research lately shows that a substantial proportion of children with autism spectrum disorder (ASD)—something on the order of 30%—show really substantial improvements in their autism symptoms,” says Amaral, ...
By NeuroPointDX
-
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO`s VGX-3100 for advanced cervical dysplasia
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. (*Complementary when referring to the US regulatory pathway.) The ...
-
Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients
SAN DIEGO & REHOVOT, ISRAEL--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology (EAU) Virtual Congress. The first abstract titled, “Real world evidence of alternating cystoscopy/cytology ...
By Nucleix Ltd.
-
BIO Announces NSF Track featuring 10 emerging biotech companies
The Biotechnology Industry Organization (BIO) today announced an agreement with the National Science Foundation (NSF) to bring SBIR-funded early-stage biotech companies to present at the 12th Annual BIO Investor Forum. The companies, funded by NSF and focused on drug discovery, diagnostics and other platform technologies, will participate in a dedicated track of company presentations. ...
-
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the completion of its study assessing the effect of food on absorption of its lead candidate CTx-1301, an investigational medication for the ...
By Cingulate
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you